RxDoctor Payments Data

Hajrah Ahsan

Hospitalist · Worcester, MANPI 1497367395

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $533 and has fallen 73.0% since, to $144 in 2025. Among hospitalist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,409in general payments, 2019–2025

Across 67 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$299
  • AstraZeneca$220
  • AbbVie$185
  • Bayer$157
  • Pfizer$127
  • Paratek Pharmaceuticals, Inc.$123
  • plus $298 from 7 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409 in reported general payments places this provider in the 95th percentile of 599 hospitalist providers in Massachusetts.

See all hospitalist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$117,459
Medicare patients
302
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$18,634
Midodrine Hcl15$1,504
Cefpodoxime Proxetil19$491
Pantoprazole Sodium45$326
Metoprolol Succinate30$290
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$197
Atorvastatin Calcium40$177
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$175
Amlodipine Besylate50$148
ClopidogrelClopidogrel Bisulfate23$105
Hydralazine Hcl15$92
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$80
Prednisone36$73
Tamsulosin Hcl19$71
Carvedilol19$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$18,63417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 hospitalist providers in Massachusetts.

Other hospitalist in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →